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ABSTRACT 
Objective: To investigate the pharmacokinetic and toxicity profiles and spectrum of biological activities of three phytochemicals isolated from 
Tarconanthus camphoratus L.  
Methods: Several integrated web based in silico pharmacokinetic tools were used to estimate the druggability of Hispidulin, Nepetin and 
Parthenolide. Afterward, the structural based virtual screening for the three compounds' potential targets was performed using PharmMapper 
online server. The molecular docking was conducted using Auto-Dock 4.0 software to study the binding interactions of these compounds with the 
targets predicted by PharmMapper server.  
Results: The permeability properties for all compounds were found within the limit range stated for Lipinski׳s rule of five. Only Parthenolide 
proved to be able to penetrate through blood brain barrier. Isopentenyl-diphosphate delta-isomerase (IPPI), uridine-cytidine kinase-2 (UCK-2) and 
the mitogen-activated protein kinase kinase-1 (MEK-1) were proposed as potential targets for Hispidulin, Nepetin and Parthenolide, respectively. 
Nepetin and Parthenolide were predicted to have anticancer activities. The activity of Nepetin appeared to be mediated through UCK-2 inhibition. 
On the other hand, inhibition of MEK-1 and enhancement of TP53 expression were predicted as the anticancer mechanisms of Parthenolide. The 
three compounds showed interesting interactions and satisfactory binding energies when docked into their relevant targets.  
Conclusion: The ADMET profiles and biological activity spectra of Hispidulin, Nepetin and Parthenolide have been addressed. These compounds 
are proposed to have activities against a variety of human aliments such as tumors, muscular dystrophy, and diabetic cataracts. 
Keywords: Tarconanthus camphoratus L., Hispidulin, Nepetin, Parthenolide, In silico pharmacokinetic, Molecular docking, PharmMapper server, 
and Auto-Dock 4.0 software  
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INTRODUCTION  
Drug discovery is concerned with finding new chemical entities, so-
called leads, having a desired biological activity [1]. Certainly, 
bioactive molecules could be identified via different approaches [2], 
but the implementations of in silico ones have reduced the cost and 
time needed to bring a drug to the market [3]. The proper 
pharmacokinetics and toxicity profile along with efficacy are the 
major determinants for successful drug development [4]. Therefore, 
poor absorption, distribution, metabolism and excretion (ADME) 
along with the toxicity (T) are the primary causes of costly late-stage 
failures in drug development. Thus, it is mandatory that these areas 
should be considered at the early stages in the drug discovery 
process [5, 6]. Towards this goal, a variety of medium and high-
throughput in vitro ADMET screens have been developed [4]. The 
high cost and lengthy time needed to conduct these in vitro screens 
have called for the development of in silico approaches. These 
approaches will render the ADMET profiles predictable resulting in a 
fast drug discovery process [3, 6]. 
The diversity of plant species has kept naturally-derived molecules 
at the core of the drug discovery process with many more molecules 
to be discovered [7]. Despite the massive researches on medicinal 
herbs, to scientifically validate their reputed curative properties, 
there are many concealed potential healing powers beyond their 
ethnomedicinal uses [8]. Herein, the medicinal plant Tarconanthus 
camphoratus L. (Family Asteraceae) is not an exception. The plant is 
known for its versatile ethnomedicinal uses including treatment of 
wounds, urinary tract infections, respiratory disorders and 
toothache relieve [9]. Moreover, it has a substantial role in the relief 
of a migraine and combating tumors [10].  
Being involved in drug discovery from natural resources [11-13], we 
have recently isolated and identified three antimicrobial 
phytochemicals namely, the sesquiterpene lactone Hispidulin and 
the two flavones Nepetin and Parthenolide (fig. 1) [10, 14]. To 
further estimate the druggability of these phytochemicals, we herein 
report their ADMET profiles and potential biological activities using 
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MATERIALS AND METHODS 
Generation of chemical structures' format 
The chemical structure of each compound, unless otherwise stated, 
was submitted in the form of canonical simplified molecular input 
line entry system (SMILE), to estimate several in silico 
pharmacokinetic parameters.  
Web based in silico pharmacokinetic tools 
Molinspiration 
Molinspiration online server (http://www.molinspiration.com/) 
[15] was used to estimate the molecular descriptors and drug 
likeliness properties for the lead candidate molecules. Estimated 
molecular properties were LogP, Topological polar surface area 
(TPSA), the number of hydrogen bond donors and acceptors. Drug 
likeliness property of the tested molecules was investigated as G-
protein coupled receptor (GPCR) ligands, ion channel modulators 
(ICM), kinase inhibitors (KI), nuclear receptor ligands (NRL), 
protease inhibitors (PI) and enzyme inhibitors (EI).  
Admet SAR  
Admet SAR online server (http://www.admetexp.org) [16] was used 
to predict ADMET profiles for the candidate leads.  
MetaPrint2D 
MetaPrint2D online server (http://www-metaprint2d.ch. 
cam.ac.uk/) [17] was used to predict metabolic transformations 
obtained for the three leads.  
PASS online tool 
PASS Online tool (http://www.pharmaexpert.ru/passonline/) [18] 
was used to predict the potential pharmacological activities and 
toxicities of the leads submitted in .sdf format.  
In silico molecular docking 
Ligand preparation 
The chemical structure of the compounds was drawn using 
ACD/ChemSketch v.12.0 software, and the obtained MDL format was 
converted into PDB format using Open Bable software [19].  
Target identification 
For each lead compound, the PharmMapper server (http:// 
59.78.96.61/pharmmapper/) [20] was used to identify its potential 
target based on its fit score. Leads were submitted in MDL. sdf 
format, the target set was limited to human targets, and all other 
parameters were kept as default. 
Protein structure retrieval and preparation 
The 3-D structures of PharmMapper server identified targets were 
retrieved from protein databank (http://www. rcsb.org/ pdb/ 
home/home.do). Afterward, the protein files were prepared by 
removal of all water molecules and hetero groups except metals (if 
any). Target structure was further optimized and energy minimized 
using Swiss PDB viewer V.4.1.0 software [21].  
In silico molecular docking 
Molecular docking was performed using Autodock 4.0 software [22], 
based on Lamarckian Genetic Algorithm; which combines energy 
evaluation through grids of affinity potential to find the suitable 
binding position for a ligand on a given protein [23]. Polar hydrogen 
atoms were added to the protein targets and Kollman united atomic 
charges were computed. All hydrogen atoms were added to the 
ligands before the Gastiger partial charges were assigned. The co-
crystal ligand was removed, and the bond orders were checked. The 
target's grid map was calculated and set to 60×60×60 points with 
grid spacing of 0.375 Ǻ. The grid box was then allocated properly in 
the target to include the active residue in the center. The default 
docking algorithms were set in accordance with standard docking 
protocol. Finally, ten independent docking runs were carried out for 
each ligand, and results were retrieved as binding energies. Poses 
that showed lowest binding energies were visualized using UCSF 
chimera [24] and MOE [25]. 
RESULTS AND DISCUSSION 
In silico pharmacokinetic estimation 
Molinspiration 
Physicochemical properties  the discovery setting, ‘Lipinski's rule of 
five’ predicts that poor absorption or permeation is more likely 
when there are more than 5 H-bond donors, 10 H-bond acceptors, 
the molecular weight is greater than 500 Da and the calculated LogP 
(CLogP) is greater than 5 (or MlogP>4.15) [26]. Moreover, good 
bioavailability is more likely for compounds with ≤10 rotatable 
bonds (nrotb) and total polar surface area (TPSA) of ≤140 Å [27]. In 
the current study, Hispidulin, Nepetin, and Parthenolide were 
predicted to have a high probability for good oral bioavailability 
where the calculated LogP values agreed with Lipinski's rule of five. 
Furthermore, TPSA, total hydrogen bond count and a number of 
rotatable bonds felt within the limit ranges (table 1). In addition, the 
number of hydrogen bond acceptors (HBA) and hydrogen bond 
donors (HBD) for each lead were found to be within Lipinski's limit 
range from 7–3 and 3–0 i.e. less than 10 and 5, respectively. Drug 
molecules of molecular weight less than 500 Da are easily 
transported, diffuse and absorbed as compared to heavy molecules 
[28]. Fortunately enough, the three leads, have molecular weights 
(MW) in the range of 248–316. 
 
Table 1: Physicochemical parameters predicted by Molinspiration for each lead 
Lead Mi logP TPSA MW HBA HBD nrotb 
Hispidulin 2.48 100.13 300.27 6 3 2 
Nepetin 1.99 120.36 316.26 7 4 2 
Parthenolide 2.09 38.83 248.32 3 0 0 
 
Druggability likeliness property of Hispidulin, Nepetin and 
Parthenolide as GPCR ligands, ion channel modulators (ICM), kinase 
inhibitors (KI), nuclear receptor ligands (NRL), protease inhibitors 
(PI) and enzyme inhibitors (EI) were studied, and results were 
retrieved as bioactivity scores. In this context, scores>0.00 indicate 
high activity, between 0.00 to −0.5 indicate moderate activity 
and<−0.5 indicate inactivity [29]. The results of the present study 
demonstrated that the three leads showed high bioactivity scores as 
NRLs and EIs (score>0.00) with Parthenolide being the most active 
(1.16 and 1.10, respectively) (table 2). Nuclear receptors (NRs) are 
important pharmaceutical targets because they are key regulators of 
many metabolic and inflammatory diseases, including diabetes, 
dyslipidemia, cirrhosis and fibrosis [30]. Based on our results, 
Parthenolide, Hispidulin, and Nepetin could be envisioned as 
potential ligands for NRs representing interesting and promising 
therapeutic alternatives to cure relevant disorders. Considerable 
bioactivity against GPCR was revealed by Parthenolide (0.43); 
Hispidulin and Nepetin, on the other hand, produced moderate 
activities (−0.07 and −0.08, respectively). Hispidulin, Nepetin and 
Parthenolide exhibited moderate activities as ion channel 
modulators (−0.22, −0.23 and −0.07, respectively). Moderate 
protease inhibition was predicted for Hispidulin and Nepetin (−0.33 
and −0.31, respectively); Parthenolide, on the other hand, was 
proposed to have satisfactory activity (0.04). While Hispidulin and 
Nepetin possessed considerable activity, Parthenolide was found 
inactive as kinase inhibitor (0.21, 0.22 and −0.55, respectively). 
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Table 2: Drug likeliness property estimations by Molinspiration for each lead 
Compound GPCR ICM KI NRL PI EI 
Hispidulin − 0.07 − 0.22 0.21 0.20 − 0.33 0.17 
Nepetin − 0.08 − 0.23 0.22 0.17 − 0.31 0.16 
Parthenolide 04.3 − 0.07 − 0.55 1.16 0.04 1.10 
 
AdmetSAR predictions 
The ADMET properties of the studied leads were calculated 
using admetSAR. Blood-Brain Barrier (BBB) penetration, HIA 
(Human Intestinal Absorption), Caco-2 cell permeability and 
AMES test were calculated. The results obtained for BBB 
penetrability greatly agreed with structures of the studied 
compounds. Only Parthenolide, a less polar sesquiterpene 
lactone, was predicted to cross BBB. It was also found that all 
tested compounds could be absorbed by the human intestine, 
and they could penetrate to Caco-2 (table 3). Nevertheless, the 
tested compounds proved to be potential substrates for P-
glycoprotein (P-gp) which effluxes drugs and various compounds 
to undergo further metabolism and clearance [31] resulting in 
therapeutic failure because the drug concentration would be 
lower than expected [32]. Many of the human microsomal P450s 
aromatase catalyze the metabolism of a wide variety of 
compounds including xenobiotic and drugs [33].  
Thus, inhibition of cytochrome P450 isoforms might cause drug-
drug interactions in which co-administered drugs fail to be 
metabolized and accumulate to toxic levels [34]. Notwithstanding, 
some of the cytochrome P450 isoforms could be inhibited by one or 
more of the tested compounds. Fortunately, all compounds did not 
show any acute toxicity and mutagenic effect with respect to the 
AMES test data. 
 
Table 3: ADMET predictions using AdmetSAR 
ADMET Lead  
Absorption Hispidulin Nepetin Parthenolide 
BBB BBB− BBB− BBB+ 
HIA HIA+ HIA+ HIA+ 
Caco-2 Caco-2+ Caco-2+ Caco-2+ 
P-gp substrate Substrate Substrate Substrate 
P-gp inhibitor Non-inhibitor Non-inhibitor  Non-inhibitor 
ROC transporter Non-inhibitor Non-inhibitor Non-inhibitor 
Distribution and metabolism 
CYP450 substrate  
CYP450 2C9 Non-substrate Non-substrate Non-substrate 
CYP450 2D6 Non-substrate Non-substrate Non-substrate 
CYP450 3A4 Non-Substrate Non-Substrate substrate 
CYP450 inhibitor  
CYP450 1A2 Inhibitor Inhibitor Inhibitor 
CYP450 2C9 inhibitor Non-inhibitor Non-inhibitor 
CYP450 2D6 Non-inhibitor Non-inhibitor Non-inhibitor 
CYP450 2C19 inhibitor Non-inhibitor Non-inhibitor 
CYP450 3A4 inhibitor inhibitor Non-inhibitor 
CYP IP (Inhibitory promiscuity) High High  Low 
Excretion and Toxicity  
HERG Weak inhibitor Weak inhibitor Weak inhibitor 
Inhibition Non-inhibitor Non-inhibitor Non-inhibitor 
AMES toxicity Non toxic Non toxic Non toxic 
Carcinogen Non-carcinogen Non-carcinogen Non-carcinogen 
Fish toxicity High  High High  
T. P toxicity High  High High  
H. B toxicity High  High High  
Biodegradation Not ready  Not ready Not ready  
Acute Oral Toxicity Category III Category III Category III 
ADMET Predicted profile---regression  
Aqueous solubility (logS) −3.2219 –3.0097 −3.4998 
Caco2 permeability (logPapp, cm/s) 0.91621 0.3244 0.2060 
Toxicity  
RAT(LD50 mol/kg) 2.71922 2.6388 0.2241 
FT (pLC50 mg/l) 0.6628 0.5863 0.4893 
TPT (PIGL50μg/l) 1.3073  1.1489 0.3812 
Key: BBB: Blood Brain Barrier, HIA: Human Intestinal Absorption, P-gp: P-Glycoprotein, ROC: Renal Organic Cation, HERG: Human Ether-a-go-go-
Related Gene, TP: Tetrahymena Pyriformis, HB: Honey Bee, RAT: Rat acute toxicity, FT: Fish toxicity. 
 
Metaprint2D predictions 
MetaPrint2D predictions revealed that the red colored allylic 
methine's carbon atom of Parthenolide and most hydroxyl groups 
for the two flavones represented good sites for metabolism (fig. 2). 
Metabolic transformations (dehydroxylation, hydroxylation, 
phosphorylation, glucuronidation, sulfation, alkylation, methylation 
and esterification) were predicted for the hydroxyl groups. 
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Fig. 2: Metabolic predictions using Metaprint2D for each lead 
 
The color highlighting an atom indicates its Normalized Occurrence 
Ratio (NOR). A high NOR indicates a more frequently reported site of 
metabolism in the metabolite database. Atoms are colored according 
to the likelihood of a metabolic site; High: red, Medium: orange, Low: 
green, very low is not colored, and No data: grey. 
PASS online server 
The chemical structure is described in PASS by original descriptors 
called Multilevel Neighbourhoods of Atoms (MNA). For each 
investigated activity, PASS calculates two probabilities, Pa and Pi, 
based on statistics of MNA descriptors. Pa and Pi values vary from 
0.000 to 1.000 indicating the probabilities of the compound to be 
active or inactive, respectively. Our findings revealed that both 
Hispidulin and Nepetin are potential chlordecone reductase 
inhibitors (Pa = 0.965 and 0.964, respectively) (table 4). The 
clinically important chlordecone reductase belongs to a family of 
enzymes known as aldo-ketoreductases. These enzymes are 
involved in the metabolism of xenobiotics and have been implicated 
in the pathogenesis of diabetic cataracts and muscular dystrophy 
[35]. Nonetheless, chlordecone reductase inhibition could be a 
drawback in the sense that risk of developing prostate cancer is 
positively associated with the chlordecone concentration in blood 
[36]. Parthenolide showed a higher probability to function as TP53 
expression enhancer (Pa = 0.980). TP53 helps protect genome 
integrity and maintain general cell homeostasis. In the presence of 
chromosomal mutations or damage, TP53 acts through multiple 
mechanisms such as apoptosis, cell cycle arrest, or cellular 
senescence halting the propagation of any mutated DNA [37]. It is 
therefore thought that the known anticancer activity of Parthenolide 
could be mediated through TP53 upregulation. 
 
Table 4: Biological activity spectrum predicted by pass for each lead 
Compound name Pa Pi Activity 
Hispidulin 0.965 0.002 Chlordecone reductase inhibitor 
Nepetin 0.964 0.002 Chlordecone reductase inhibitor 
Parthenolide 0.980 0.002 TP53 expression enhancer 
Pa: probablyactive; Pi: probablyinactive 
 
In silico molecular docking  
PharmMapper server has predicted that isopentenyl-diphosphate 
delta isomerase (IPPI) (PDB ID: 1PPV), uridine-cytidine kinase-2 
(UCK-2) (PDB ID: 1UDW) and the mitogen-activated protein kinase 
kinase-1 (MEK-1) (PDB ID: 1S9J) are the best targets, in terms of fit 
scores (3.958, 4.702 and 4.338), for Hispidulin, Nepetin and 
Parthenolide, respectively.  
IPPI is expressed in both prokaryotic and eukaryotic organisms [38]. 
The enzyme catalyzes isomerization of isopentenyl diphosphate 
(IPP) to dimethylallyl pyrophosphate (DMAPP) [39], which are 
important precursors for several compounds involved in signaling 
pathway and components of the cell membrane [40]. The IPPI key 
active-site residues are Glu-116, Tyr-104, and Cys-67, with Glu-116 
being thought to protonate the IPP double bond while the Cys-67 
thiolate removes a proton from C-2 of IPP. The active residue Tyr-
104, which is hydrogen bonded to Glu-116 [41] is also thought to be 
involved with Glu-116 in protonating the double bond in IPP [42]. 
Hispidulin was successfully docked into IPPI with a binding energy 
of −8.36 kcal/mol. Analysis of the binding interactions revealed that 
Hispidulin formed a hydrogen bond with the active residue Tyr-104 
(fig. 3). Contrary to other known IPPI inhibitors [42], Hispidulin did 
not interact directly with the active residues Glu-116 or Cys-67. 
Nevertheless, the above-mentioned interaction of Hispidulin with 
Tyr-104 altered the Glu-116/Tyr-104 hydrogen bonding resulting in 
a recognizable conformational change in the active pocket. Thus, the 
active pocket will no longer be complementary with the natural 
substrate. Apart from the active residues, Hispidulin formed 
hydrogen bonds with Cys-118, Phe-35, and Gly-68 that helped to 
allocate Hispidulin in the vicinity, between Glu-116 and Cys-67, 
where IPP isomerizes. In addition, Hispidulin-IPPI complex was 
further stabilized through interactions with both divalent metals and 
hydrophobic residues (fig. 3). 
Being an IPPI inhibitor, Hispidulin can be considered as a 
potential lead for development of novel drugs for infectious [43, 
44] and non-infectious [45] diseases with which IPP pathway is 
associated. Nevertheless, host toxicity should be taken into 
consideration regarding the development of Hispidulin as an 
anti-infectious drug.  
Docking of Nepetin into UCK-2 enzyme (binding energy = −10.05 
kcal/mol) showed hydrogen bonding with Arg-176 and His-117, 
which are known binding residues for the inhibitor cytidine 
triphosphate (fig. 4). In addition, Nepetin interacted via hydrogen 
bonding with Arg-166 and Arg-169.  
These residues are important binding sites for other UCK-2 
inhibitors [46]. The UCK-2 enzyme is normally expressed in human 
placenta and testis and overexpressed in many neoplasias of blood 
and solid tissues [47]. It is worth noting that Nepetin has been 
shown to have anticancer activity [48]. It appears that this activity 
could be mediated through UCK-2 inhibition. 
Parthenolide docked nicely within the active pocket of MEK-1 
enzyme (binding energy = −6.42 kcal/mol). Literature revealed that 
MEK-1 inhibitors form an essential hydrogen bond with catalytic 
Lys-97 in addition to hydrophobic interactions with the deep 
hydrophobic pocket formed by Met-143, Ile-141, Leu-118 and Phe-
209 [49]. Interestingly, Parthenolide showed similar interactions 
with MEK-1 active pocket (fig. 5).  
These interactions would render MEK-1 catalytically inactive by 
stabilizing the inactive conformation of the activation loop. It is 
worth noting that MEK-1 plays a curial role in normal cell survival, 
however, altered expression level was detected in various types of 
cancer [50]. Thus, the known anticancer activity of Parthenolide [51] 
can be explained by MEK-1 inhibition. 
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Fig. 3: Hispidulin-IPPI interactions visualized by Chimera (left) and MOE (right) 
 
  
Fig. 4: Nepetin-UCK-2 interactions visualized by Chimera (left) and MOE (right) 
 
  
Fig. 5: Parthenolide-MEK-1 interactions visualized by Chimera (left) and MOE (right) 
 
CONCLUSION 
The ADMET profiles for the antimicrobials; Hispidulin, Nepetin and 
Parthenolide, isolated from Tarconanthus camphoratus L., have been 
estimated using different web based in silico tools. In addition, their 
biological activity spectra were also investigated. The sesquiterpene 
lactone Parthenolide was proposed to have potential antitumor 
activity through inhibition of MEK-1 or enhancement of TP53 
expression. The flavone Nepetin was also predicted to have 
anticancer activity mediated by UCK-2 inhibition. Nepetin and the 
other flavone Hispidulin were proposed to play a role in the 
treatment of diabetic cataracts and muscular dystrophy through 
inhibition of chlordecone reductase enzyme.  
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